title: [Phagotherapy: a nightmare for bacteria, a dream for physicians?].
abstract: Bacteriophages were discovered in the early 20th century and rapidly used to treat bacterial infections in humans. As the first specific antibacterial agents, they were used worldwide until antibiotics ramped up. Thereafter, rapidly forgotten, they became the favorite toolbox for researchers that used them to elucidate some of the most fundamental aspects of the cellular life at the molecular level. Today, facing the threat of antibiotic resistant bacteria, bacteriophages are being reconsidered for their use in medicine. During the past century, knowledge on bacteriophages has improved considerably, nevertheless phage therapy is still in its infancy. Taking two examples of recently published experimental phage therapy results, this article summarizes the hopes but also the challenges that surround the future development of human phage therapy.
authors: Institut Pasteur, Département de Microbiologie, 25 Rue du Dr Roux, 75724 Paris Cedex 15, France.
authors: Laurent
authors: L
authors: Debarbieux
authors: Institut Pasteur, Département de Microbiologie, 25 Rue du Dr Roux, 75724 Paris Cedex 15, France.
authors: Emilie
authors: E
authors: Saussereau
authors: Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, 02114 Massachusetts, USA - Department of Microbiology and Immunobiology, Harvard Medical School, Boston, 02114 Massachusetts, USA - Shriners Hospitals for Children-Boston, Boston, 02114 Massachusetts, USA.
authors: Damien
authors: D
authors: Maura
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000628:therapy*; D001435:Bacteriophages / Q000502:physiology*; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D004927:Escherichia coli Infections / Q000628:therapy; D006801:Humans; D007410:Intestinal Diseases / Q000382:microbiology; D008171:Lung Diseases / Q000382:microbiology*; D011552:Pseudomonas Infections / Q000628:therapy; D011550:Pseudomonas aeruginosa